• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comparison of change in lipoprotein(a) mass and molar concentrations by alirocumab and risk of subsequent cardiovascular events in ODYSSEY OUTCOMES.

作者信息

Szarek Michael, Reijnders Esther, Steg Ph Gabriel, Jukema J Wouter, Schwertfeger Markus, Bhatt Deepak L, Bittner Vera A, Diaz Rafael, Fazio Sergio, Garon Genevieve, Goodman Shaun G, Harrington Robert A, White Harvey D, Zeiher Andreas M, Cobbaert Christa, Schwartz Gregory G

机构信息

Division of Cardiology, University of Colorado School of Medicine, Box B130, Aurora, CO 80045, USA.

CPC Clinical Research, 2115 N. Scranton Street, Suite 2040, Aurora, CO 80045, USA.

出版信息

Eur J Prev Cardiol. 2024 Aug 9;31(10):e75-e78. doi: 10.1093/eurjpc/zwae110.

DOI:10.1093/eurjpc/zwae110
PMID:38501249
Abstract
摘要

相似文献

1
Comparison of change in lipoprotein(a) mass and molar concentrations by alirocumab and risk of subsequent cardiovascular events in ODYSSEY OUTCOMES.在ODYSSEY OUTCOMES研究中，阿利西尤单抗对脂蛋白(a)质量和摩尔浓度变化的影响及其与后续心血管事件风险的比较。
Eur J Prev Cardiol. 2024 Aug 9;31(10):e75-e78. doi: 10.1093/eurjpc/zwae110.
2
Peripheral Artery Disease and Venous Thromboembolic Events After Acute Coronary Syndrome: Role of Lipoprotein(a) and Modification by Alirocumab: Prespecified Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial.急性冠状动脉综合征后外周动脉疾病和静脉血栓栓塞事件：脂蛋白(a)的作用和依洛尤单抗的修饰：ODYSSEY OUTCOMES 随机临床试验的预设分析。
Circulation. 2020 May 19;141(20):1608-1617. doi: 10.1161/CIRCULATIONAHA.120.046524. Epub 2020 Mar 29.
3
The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism.PCSK9（前蛋白转化酶枯草溶菌素 9）抑制对静脉血栓栓塞风险的影响。
Circulation. 2020 May 19;141(20):1600-1607. doi: 10.1161/CIRCULATIONAHA.120.046397. Epub 2020 Mar 29.
4
Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials.PCSK9 抑制剂对脂蛋白(a)的降低作用与主要不良心血管事件：依洛尤单抗 3 期临床试验的汇总分析。
Atherosclerosis. 2019 Sep;288:194-202. doi: 10.1016/j.atherosclerosis.2019.06.896. Epub 2019 Jun 8.
5
What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER?我们从PCSK9抑制剂的ODYSSEY和FOURIER结果试验中对脂质与心血管风险有了哪些了解？
Cardiovasc Res. 2019 Mar 1;115(3):e26-e31. doi: 10.1093/cvr/cvy301.
6
Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.阿利西尤单抗治疗 2 型糖尿病合并动脉粥样硬化性心血管疾病患者：ODYSSEY DM-DYSLIPIDEMIA 和 DM-INSULIN 研究分析。
Cardiovasc Diabetol. 2019 Nov 9;18(1):149. doi: 10.1186/s12933-019-0951-9.
7
Associations between lower levels of low-density lipoprotein cholesterol and cardiovascular events in very high-risk patients: Pooled analysis of nine ODYSSEY trials of alirocumab versus control.在极高危患者中，低密度脂蛋白胆固醇水平较低与心血管事件之间的关联：依洛尤单抗与对照的 9 项 ODYSSEY 试验的汇总分析。
Atherosclerosis. 2019 Sep;288:85-93. doi: 10.1016/j.atherosclerosis.2019.07.008. Epub 2019 Jul 12.
8
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation.PCSK9 抑制剂阿利西尤单抗的安全性：来自 47296 患者年观察的结果。
Eur Heart J Cardiovasc Pharmacother. 2024 Jul 16;10(4):342-352. doi: 10.1093/ehjcvp/pvae025.
9
Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes.使用新的美国心脏病学会/美国心脏协会胆固醇管理指南进行风险分类及其与急性冠状动脉综合征后依洛尤单抗治疗的关系。
Circulation. 2019 Nov 5;140(19):1578-1589. doi: 10.1161/CIRCULATIONAHA.119.042551. Epub 2019 Sep 2.
10
PCSK9 Inhibitors in Secondary Prevention-An Opportunity for Personalized Therapy.PCSK9 抑制剂在二级预防中的应用——个性化治疗的机会。
J Cardiovasc Pharmacol. 2020 May;75(5):410-420. doi: 10.1097/FJC.0000000000000809.

引用本文的文献

1
Elevated lipoprotein(a) and its association with early-onset myocardial infarction and coronary burden.脂蛋白(a)升高及其与早发心肌梗死和冠状动脉负荷的关联。
Arch Cardiol Mex. 2025;95(2):188-193. doi: 10.24875/ACM.24000183.
2
Lipoprotein(a) and Cardiovascular Risk: New Insights.脂蛋白(a)与心血管风险：新见解
Eur J Prev Cardiol. 2024 Nov 15. doi: 10.1093/eurjpc/zwae378.
3
Recommendations of the Experts of the Polish Cardiac Society (PCS) and the Polish Lipid Association (PoLA) on the diagnosis and management of elevated lipoprotein(a) levels.
波兰心脏病学会（PCS）和波兰脂质协会（PoLA）专家关于脂蛋白(a)水平升高的诊断和管理的建议。
Arch Med Sci. 2024 Jan 31;20(1):8-27. doi: 10.5114/aoms/183522. eCollection 2024.